- Types of Eczema
- Child Eczema
- Living Well
- Eczema Products
- Get Involved
Following on the heels of Dupixent (dupilumab)—the first-ever biologic drug for atopic dermatitis (the most common type of eczema), approved by the U.S. Food and Drug Administration (FDA) on March 28—a second biologic may soon be on the way.
ICER, a nonprofit that conducts independent reviews on clinical effectiveness and value of treatments, found Dupixent to be a “high value” drug for adults with atopic dermatitis.
A newly approved treatment finally brings relief to a woman who’s coped with severe eczema for more than 70 years.
In March, the FDA approved Dupixent, the first biologic medication for adults with moderate to severe atopic dermatitis. Clinical research investigator Dr Paul Yamauchi answers questions about the new medication.
The U.S. Food and Drug Administration approved Dupixent (dupilumab), the first biologic medication for adults with moderate to severe atopic dermatitis (AD).
What are biologics? Biologic drugs, or biologics, are among the most targeted therapies available today because they essentially use human DNA to treat certain diseases at the immune system level. Taken subcutaneously (through the skin) or intravenously (in the vein), biologics are genetically engineered medications that contain proteins derived from living tissues or cells cultured […]
Atopic dermatitis is a hot field of study. Here’s some highlights on eczema research and care from this year’s AAD meeting.
As more treatments for AD are approved by the FDA, your health insurance company may restrict your ability to access new drugs in order to control costs. The following are some of the most common tactics health insurance companies use to restrict access to certain treatments and medical care.
Biologic medications are already being used to treat diseases including rheumatoid arthritis, psoriasis and Crohn’s disease, as well as others. So, what are biologic drugs and what do people need to know if they are considering them to treat their AD?